miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11 Corrigendum in /or/32/3/1319

Niu,Huanjiang; Wang,Kun; Zhang,Anling; Yang,Shuxu; Song,Zhengfei; Wang,Wei; Qian,Cong; Li,Xinwei; Zhu,Yinxin; Wang,Yirong

doi:10.3892/or.2012.1970

November 2012 Volume 28 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2012 Volume 28 Issue 5

Full Size Image

Article

miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11

Corrigendum in: /or/32/3/1319

Authors:
- Huanjiang Niu
- Kun Wang
- Anling Zhang
- Shuxu Yang
- Zhengfei Song
- Wei Wang
- Cong Qian
- Xinwei Li
- Yinxin Zhu
- Yirong Wang
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou 310016, P.R. China, Department of Neurosurgery, Hangzhou Xiasha Hospital, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou 310016, P.R. China, Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Pharmacy, Hangzhou Xiasha Hospital, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou 310016, P.R. China
Pages: 1771-1777
|
Published online on: August 10, 2012

https://doi.org/10.3892/or.2012.1970
Expand metrics +

Abstract

Recent studies have revealed that miR-92a is overexpressed in several types of malignancies and provides a protumorigenic effect. Our findings demonstrate that the high expression of miR-92a in human glioma specimens is significantly correlated with low levels of BCL2L11 (Bim) protein and high-grade glioma. Here, we present the first evidence that miR-92a antisense oligonucleotide (AS-miR-92a) provides a tumor suppressive effect via induction of apoptosis in human glioma cells. In addition, we show that Bim is a direct functional target of miR-92a. Introducing Bim cDNA without 3'UTR abrogates miR-92a-induced cell survival. Further investigations will focus on the therapeutic use of AS-miR‑92a-mediated antitumor effects in glioma.

View Figures

View References

1	Surawicz TS, McCarthy BJ, Kupelian V, et al: Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1:14–25. 1999.PubMed/NCBI
2	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hadjipanayis CG and Van Meir EG: Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med. 87:363–374. 2009. View Article : Google Scholar : PubMed/NCBI
4	Purow B and Schiff D: Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol. 5:419–426. 2009. View Article : Google Scholar : PubMed/NCBI
5	Elmén J, Lindow M, Schütz S, et al: LNA-mediated microRNA silencing in non-human primates. Nature. 452:896–899. 2008.PubMed/NCBI
6	Meister G and Tuschl T: Mechanisms of gene silencing by double stranded RNA. Nature. 431:343–349. 2004. View Article : Google Scholar : PubMed/NCBI
7	Tijsterman M and Plasterk RH: Dicers at RISC; the mechanism of RNAi. Cell. 117:1–3. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
9	Jovanovic M and Hengartner MO: miRNAs and apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006. View Article : Google Scholar : PubMed/NCBI
10	He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
11	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
12	Metzler M, Wilda M, Busch K, et al: High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer. 39:167–169. 2004. View Article : Google Scholar : PubMed/NCBI
13	Murakami Y, Yasuda T, Saigo K, et al: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
14	Shigoka M, Tsuchida A, Matsudo T, et al: Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 60:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
15	Chen ZL, Zhao XH, Wang JW, et al: microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
16	Haug BH, Henriksen JR, Buechner J, et al: MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis. 32:1005–1012. 2011. View Article : Google Scholar : PubMed/NCBI
17	Tsuchida A, Ohno S, Wu W, et al: miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci. 102:2264–2271. 2011. View Article : Google Scholar : PubMed/NCBI
18	Spannuth WA, Sood AK and Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 5:194–204. 2008. View Article : Google Scholar : PubMed/NCBI
19	Arnoult D: Apoptosis-associated mitochondrial outer membrane permeabilization assays. Methods. 44:229–234. 2008. View Article : Google Scholar : PubMed/NCBI
20	Zhou X, Ren Y, Moore L, et al: Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
21	Yamamichi N, Shimomura R, Inada K, et al: Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res. 15:4009–4016. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yee KS, Wilkinson S, James J, et al: PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 16:1135–1145. 2009. View Article : Google Scholar : PubMed/NCBI
23	Talotta F, Cimmino A, Matarazzo MR, et al: An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene. 28:73–84. 2009. View Article : Google Scholar : PubMed/NCBI
24	Thaker NG and Pollack IF: Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother. 9:1815–1836. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nana-Sinkam SP and Croce CM: MicroRNAs as therapeutic targets in cancer. Transl Res. 157:216–225. 2011. View Article : Google Scholar : PubMed/NCBI
26	Law PT and Wong N: Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 26:437–449. 2011. View Article : Google Scholar : PubMed/NCBI
27	Gandellini P, Profumo V, Folini M, et al: MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
28	Farazi TA, Spitzer JI, Morozov P, et al: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar
29	Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
30	Piñon JD, Labi V, Egle A, et al: Bim and Bmf in tissue homeostasis and malignant disease. Oncogene. 27:S41–S52. 2008.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11

Corrigendum in: /or/32/3/1319

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles